(NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada
2018;41(7):e1134
It tests semaglutide for alcohol use disorder in veterans who are currently drinking, and measures whether they drink less
Without it, many GLP-1 and GIP prescriptions will not be covered by health insurance
Last reviewed: June 19, 2026 Last updated: June 19, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
NCT06383390: TRIUMPH-Outcomes: A Phase 3 Study to Investigate the Effect of Retatrutide on MACE and MAKE